Edition:
India

Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

6.24USD
1:06am IST
Change (% chg)

$-0.19 (-2.88%)
Prev Close
$6.42
Open
$6.50
Day's High
$6.66
Day's Low
$6.20
Volume
38,700
Avg. Vol
98,652
52-wk High
$23.33
52-wk Low
$4.21

Latest Key Developments (Source: Significant Developments)

Adamas Reports Q2 Loss Per Share $0.90
Friday, 9 Aug 2019 

Aug 8 (Reuters) - Adamas Pharmaceuticals Inc ::ADAMAS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.90.Q2 EARNINGS PER SHARE ESTIMATE $-0.98 -- REFINITIV IBES DATA.ALFRED MERRIWEATHER, CFO, TO RETIRE; CHRIS PRENTISS, SVP FINANCE AND CHIEF ACCOUNTING OFFICER, NAMED AS SUCCESSOR.  Full Article

Adamas Pharmaceuticals Reports Q3 Loss Per Share $1.22
Friday, 2 Nov 2018 

Nov 1 (Reuters) - Adamas Pharmaceuticals Inc ::ADAMAS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $1.22.Q3 EARNINGS PER SHARE VIEW $-1.34 -- THOMSON REUTERS I/B/E/S.Q3 SALES $10.6 MILLION VERSUS I/B/E/S VIEW $10.2 MILLION.ADAMAS ENDED QUARTER WITH $233.2 MILLION OF CASH, CASH EQUIVALENTS, AND AVAILABLE-FOR-SALE SECURITIES.  Full Article

Adamas Pharmaceuticals Announces Publication Of Data Supporting The Benefits Of Gocovri™ In Parkinson’s Disease Patients With Dyskinesia
Thursday, 15 Mar 2018 

March 15 (Reuters) - Adamas Pharmaceuticals Inc ::ADAMAS PHARMACEUTICALS INC -.ADAMAS ANNOUNCES PUBLICATION OF DATA SUPPORTING THE BENEFITS OF GOCOVRI™ IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA.ADAMAS PHARMACEUTICALS - ANNOUNCES RESULTS FROM TWO POOLED PHASE 3 STUDIES IN PARKINSON'S DISEASE PATIENTS WITH DYSKINESIA.ADAMAS PHARMACEUTICALS - THE 2 POOLED PHASE 3 STUDIES SHOWED GOCOVRI-TREATED PATIENTS EXPERIENCED 41 PERCENT FALL IN DYSKINESIA FROM BASELINE AT WEEK 12.  Full Article

Adamas Pharmaceuticals Says ‍As Of Feb 28, Co Received Prescriptions For Gocovri From About 390 Distinct Prescribers
Monday, 12 Mar 2018 

March 12 (Reuters) - Adamas Pharmaceuticals Inc ::ADAMAS PHARMACEUTICALS SAYS ‍AS OF FEB 28, CO RECEIVED PRESCRIPTIONS FOR GOCOVRI FROM ABOUT 390 DISTINCT PRESCRIBERS - SEC FILING​.ADAMAS PHARMACEUTICALS INC - ‍FILLED GOCOVRI PRESCRIPTIONS FOR PERIOD FROM JAN 1, 2018, THROUGH FEB 28, 2018, WERE 742​.  Full Article

Adamas Q4 Loss Per Share $1.27
Friday, 23 Feb 2018 

Feb 22 (Reuters) - Adamas Pharmaceuticals Inc ::ADAMAS REPORTS RECENT ACHIEVEMENTS AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR 2017.Q4 LOSS PER SHARE $1.27.SAYS FOR 2018, ADAMAS EXPECTS FULL-YEAR RESEARCH AND DEVELOPMENT EXPENSES TO BE BETWEEN $45 MILLION AND $50 MILLION.QUARTERLY TOTAL NET REVENUES $568,000 VERSUS $37,000.  Full Article

Adamas prices offering Of 3 mln shares at $41.50 per share
Wednesday, 24 Jan 2018 

Jan 23 (Reuters) - Adamas Pharmaceuticals Inc ::ADAMAS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.ADAMAS PHARMACEUTICALS INC - ‍PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 3 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $41.50 PER SHARE​.  Full Article

Adamas Pharmaceuticals reports Q3 loss per share $1.04
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Adamas Pharmaceuticals Inc :Adamas Pharmaceuticals Inc reports recent achievements and third quarter 2017 financial results.Q3 loss per share $1.04.Q3 earnings per share view $-0.98 -- Thomson Reuters I/B/E/S.Adamas Pharmaceuticals Inc - ‍ expects to receive $65 million in funding from healthcare royalty partners in q4 of 2017.Adamas Pharmaceuticals Inc - ‍ believe we will be sufficiently capitalized to launch and commercialize gocovri, among others​.  Full Article

Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Adamas Pharmaceuticals Inc :Kerrisdale Advisers LLC reports a 6.5 percent passive stake in Adamas Pharmaceuticals as of October 24 - SEC filing‍​.  Full Article

Point72 Asset Management reports 5.1 pct passive stake in Adamas Pharma‍​
Saturday, 28 Oct 2017 

Oct 27 (Reuters) - Adamas Pharmaceuticals Inc :Point72 Asset Management L.P reports a 5.1 percent passive stake in Adamas Pharmaceuticals Inc as of October 26, 2017 - SEC filing‍​.  Full Article

Adamas Pharmaceuticals says FDA recognizes orphan drug exclusivity for GOCOVRI
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Adamas Pharmaceuticals Inc ::FDA recognizes orphan drug exclusivity for Adamas’ GOCOVRI.  Full Article